KRONOS BIO NEW.jpg
Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer
23 sept. 2024 08h55 HE | Kronos Bio, Inc.
– New data show istisociclib (KB-0742) triggered cell death in preclinical ovarian cancer models of platinum and PARP-inhibitor (PARPi) resistance – – New PK/PD results demonstrate that istisociclib...
KRONOS BIO NEW.jpg
Kronos Bio Announces Participation in Medical and Investor Conferences in September
03 sept. 2024 08h55 HE | Kronos Bio, Inc.
SAN MATEO, Calif., and CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and...
indaptus_logo.png
Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting
11 avr. 2024 07h30 HE | Indaptus Therapeutics
NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection...
indaptus_logo.png
Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting
25 mars 2024 08h30 HE | Indaptus Therapeutics
Data demonstrates that Company’s Decoy platform successfully induces or activates multiple immune cell types involved in anti-tumor responses New data shows activity in M1 macrophages, natural...
HCW Logo_Full_Color_600x_JPEG (2).jpg
HCW Biologics Poster Presentation at AACR Annual Meeting 2023
13 avr. 2023 07h15 HE | HCW Biologics, Inc
Presentation of data for the mechanism underlying HCW9218 against solid tumors HCW9218 is the clinical-stage, lead product candidate of HCW Biologics Inc. MIRAMAR, Fla., April 13, 2023 (GLOBE...
Senti.png
Senti Bio Presents New Preclinical Data on Cancer-Killing Allogeneic CAR-NK Cells at AACR Annual Meeting
08 avr. 2022 13h00 HE | Senti Bio
- Preclinical data demonstrate the use of gene circuits to improve the therapeutic potential of allogeneic CAR-NK cells for the treatment of solid tumors - - CAR-NK cells armed with calibrated...
Senti.png
Senti Bio to Present Preclinical Data on Cancer-Killing Allogeneic CAR-NK Cells at AACR Annual Meeting
08 mars 2022 16h30 HE | Senti Bio
SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Senti Bio, a leading gene circuit company, today announced the acceptance of an abstract for presentation at the American Association...